Low-level Viremia in Treated HIV-1 Infected Patients: Advances and Challenges

被引：9
作者：
Bai, Ruojing [1 ]
Lv, Shiyun [2 ]
Wu, Hao [1 ]
Dai, Lili [2 ]
机构：
[1] Capital Med Univ, Beijing Youan Hosp, Ctr Infect Dis, Beijing 100069, Peoples R China
[2] Capital Med Univ, Beijing Youan Hosp, Ctr Infect Dis, Travel Clin, Beijing, Peoples R China
来源：
CURRENT HIV RESEARCH | 2022年 / 20卷 / 02期
基金：
北京市自然科学基金;
关键词：
Antiretroviral therapy; HIV-1; infection; low-level viremia; virological failure; reservoir; clinical management; ANTIRETROVIRAL DRUG-RESISTANCE; IMMUNODEFICIENCY-VIRUS TYPE-1; PERSISTENT HIV-1 REPLICATION; TO-CHILD TRANSMISSION; IMMUNE RECONSTITUTION; VIROLOGICAL FAILURE; TRANSIENT VIREMIA; INFECTED PATIENTS; NO EVIDENCE; RNA LEVELS;
D O I：
10.2174/1570162X20666220216102943
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Antiretroviral therapy (ART) can effectively suppress HIV-1 replication, improving quality of life and restoring the lifespan of persons living with HIV (PLWH) to near-normal levels. However, after standardized ART, a low level of HIV-1 RNA, i.e., low-level viremia (LLV), may still be identified in 3% to 10% of the patients. LLV is capable of impacting the immunological and clinical outcomes of patients and serves as a risk factor for transmission. The underlying mechanism of LLV is not yet certain, and the effects of LLV on patient outcomes remain under evaluation. Understanding LLV will allow effective prevention and control strategies to be designed for the benefit of PLWH.
引用
收藏
页码：111 / 119
页数：9
相关论文
共 75 条
  • [1] [Anonymous], 2019, HIV Med, V20 Suppl 9, P3, DOI 10.1111/hiv.12814
  • [2] [Anonymous], 2021, DHHS PANEL ANTIRETRO
  • [3] Low-Level Viremia Is Associated With Clinical Progression in HIV-Infected Patients Receiving Antiretroviral Treatment
    Bernal, Enrique
    Gomez, Jose M.
    Jarrin, Inma
    Cano, Alfredo
    Munoz, Angeles
    Alcaraz, Antonia
    Imaz, Arkaitz
    Iribarren, Jose A.
    Rivero, Maria
    Arazo, Piedad
    Gutierrez, Felix
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2018, 78 (03) : 329 - 337
  • [4] Residual immune dysfunction under antiretroviral therapy
    Cai, Catherine W.
    Sereti, Irini
    [J]. SEMINARS IN IMMUNOLOGY, 2021, 51
  • [5] Calvez V., 2017, 16 EUR AIDS C EACS 2
  • [6] Persistent low-level HIV-1 RNA between 20 and 50 copies/mL in antiretroviral-treated patients: associated factors and virological outcome
    Charpentier, Charlotte
    Landman, Roland
    Laouenan, Cedric
    Joly, Veronique
    Hamet, Gwenn
    Damond, Florence
    Brun-Vezinet, Francoise
    Mentre, France
    Descamps, Diane
    Yeni, Patrick
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2012, 67 (09) : 2231 - 2235
  • [7] HIV reservoirs: what, where and how to target them
    Churchill, Melissa J.
    Deeks, Steven G.
    Margolis, David M.
    Siliciano, Robert F.
    Swanstrom, Ronald
    [J]. NATURE REVIEWS MICROBIOLOGY, 2016, 14 (01) : 55 - 60
  • [8] Low-Level Viremia in HIV-1 Infection: Consequences and Implications for Switching to a New Regimen
    Cohen, Calvin
    [J]. HIV CLINICAL TRIALS, 2009, 10 (02): : 116 - 124
  • [9] Residual Viremia in Treated HIV+ Individuals
    Conway, Jessica M.
    Perelson, Alan S.
    [J]. PLOS COMPUTATIONAL BIOLOGY, 2016, 12 (01)
  • [10] Immune reconstitution under antiretroviral therapy: the new challenge in HIV-1 infection
    Corbeau, Pierre
    Reynes, Jacques
    [J]. BLOOD, 2011, 117 (21) : 5582 - 5590
12345678